Coeptis Therapeutics (COEP) and Its Competitors Head-To-Head Contrast

Coeptis Therapeutics (NASDAQ:COEP) is one of 284 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Coeptis Therapeutics to related companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, analyst recommendations and earnings.

Insider & Institutional Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Coeptis Therapeutics has a beta of -0.89, suggesting that its share price is 189% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ peers have a beta of 1.05, suggesting that their average share price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Coeptis Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	1	0	3.00
Coeptis Therapeutics Competitors	1400	4399	11374	204	2.60

Coeptis Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 796.06%. As a group, “Biological products, except diagnostic” companies have a potential upside of 81.79%. Given Coeptis Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Coeptis Therapeutics is more favorable than its peers.

Earnings and Valuation

This table compares Coeptis Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	-$21.27 million	-0.40
Coeptis Therapeutics Competitors	$543.69 million	-$31.26 million	7.25

Coeptis Therapeutics’ peers have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Coeptis Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Coeptis Therapeutics Competitors	-2,556.29%	-232.34%	-45.91%

Summary

Coeptis Therapeutics peers beat Coeptis Therapeutics on 7 of the 13 factors compared.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.